NYSE
9.79USD
-0.30 (-2.97%)
We have scored 79 news catalysts on Phreesia, Inc. (PHR) over the past 12 months. The biggest single-day move next to one of them came Jun 28, 2026, when PHR closed +10.3%: “Bronstein, Gewirtz & Grossman LLC Urges Veritone, Inc. Investors to Act: Class Action Filed Alleging Investor Harm”. Coverage across the window leans negative (average ticker sentiment −0.73). Most of the impact sits in price momentum and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
603.6M
P/E
—
EPS
—
Beta
0.86
52W range
7.77-24.245
Day range
9.78–10.20
Open
10.06
Prev close
10.10
Volume
195.2K
Avg volume
1.1M
Dividend
0.00
IPO
2019-07-18
Analysts publish price targets on PHR, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
9 analyst price targets from $9 to $16
as of 2026-09-10
The market is 14% below the median target — more cautious than the analysts.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Phreesia, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for PHR: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Phreesia, Inc. offers a comprehensive, cloud-based software-as-a-service (SaaS) and payment platform specifically designed for the healthcare industry in the United States and Canada. Its flagship Phreesia Platform streamlines the patient intake process and facilitates integrated patient payment processing. The platform is accessible via multiple modalities, including Phreesia Mobile (a patient-facing mobile application), Phreesia Dashboard (a web-based portal for healthcare clients), self-service tablets known as PhreesiaPads, and on-site Arrivals Kiosks. The Phreesia Platform integrates a suite of specialized modules: An automated patient self-registration system. A revenue cycle management solution providing insurance verification, point-of-sale payment applications, and cost estimation tools. Access solutions for online appointment scheduling, reminders, and referral tracking. A life sciences solution delivering targeted, clinically relevant marketing content to patients. Additionally, a clinical support solution gathers clinical intake and patient-reported outcome (PRO) data across approximately 25 specialties, and enables healthcare clients to communicate with patients via surveys, announcements, text and email messaging, and health campaigns. Dedicated COVID-19 support modules assist with vaccine delivery management, identifying vaccine-hesitant individuals, screening for risk factors, facilitating contactless check-in, and managing telehealth visit intake. Phreesia serves a diverse clientele, including individual patients; single and multi-specialty practices, along with health systems; and pharmaceutical, medical device, and biotechnology firms. Established in 2005, the company maintains its headquarters in Raleigh, North Carolina.
The reconstruction
The price sits at the 33rd percentile of published models, rejecting five bull cases to lean bearish, which means it fully assumes the recently announced growth deceleration and resulting legal risk.
What the disagreement turns on
Whether the Network Solutions segment's pharmaceutical advertising revenue is undergoing a temporary pause or a permanent contraction, and the wired data can only measure the resulting volume trend — not the advertiser intent behind it.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $10.34 on 2026-09-10 — the quote has since moved -5%, so read this as a record of what was priced in then, not now.
